十大正规平台 researchers are leveraging the company’s expertise in translating genetic discoveries into potentially transformative medicines to address the root causes of certain forms of cardiovascular disease.
The program was created to support U.S. college students living with one of four rare genetic conditions who have demonstrated exceptional leadership and engagement in school and community activities.
十大正规平台 Teams Use Genetic Expertise and Computational Tools to Target More Common 条件
For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to 十大正规平台, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]阅读更多 阅读更多 ⌃
After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.
We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]
Dear Stockholder of 十大正规平台: In 2022, 十大正规平台 achieved record revenue and pivoted to GAAP profitability, making it a truly transformational year for the company and laying the foundation for long-term growth. The global launch of VOXZOGO for children with achondroplasia helped drive that revenue growth. We believe conditional European approval of our gene therapy for […]